It is worth noting that in recent years, scientists have developed a PEG-PEI-cholesterol (PPC) lipopolymer delivery system to successfully achieve targeted delivery of gene editing elements into xenograft tumor in vivo and achieved approximately 50% gene knockouts in osteosarcoma cells, mainly by delivering the LC09 lipopolymer encapsulating the plasmid encoding VEGFA gRNA and Cas9 to osteosarcoma in situ and lung metastatic sites. This evidence concerns the gene VEGFA and osteosarcoma.